Lung Cancer

Lung Cancer News

  • ASCO Pembrolizumab Flat Dosing Wastes Nearly $1 Billion Annually Flat dosing of pembrolizumab results in a 25% increase in drug dose and cost compared with personalized dosing. An expert argues that flat dosing allows the waste to be hidden by its being dumped into the patient and urges transparency on drug costs.
  • Alert FDA Approves Targeted Drug Combo for Lung Cancer For the first time, the FDA has approved treatment for metastatic non-small cell lung cancer with BRAF V600E mutation.

Lung Cancer Perspective